{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:21:56Z","timestamp":1793892116826,"version":"4.8.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacbts.2026.101595","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:06:45Z","timestamp":1781294805000},"page":"101595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4077-1232","authenticated-orcid":false,"given":"Piotr","family":"Mazur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8971","authenticated-orcid":false,"given":"Magdalena","family":"Kopytek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-8007","authenticated-orcid":false,"given":"Joanna","family":"Natorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2026.101595_bib1","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/jpm11121292","article-title":"Towards personalized therapy of aortic stenosis","volume":"11","author":"Mazur","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacc.2015.05.066","article-title":"Calcification in aortic stenosis: the skeleton key","volume":"66","author":"Pawade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2026.101595_bib3","first-page":"1","article-title":"Pathophysiology of aortic stenosis and future perspectives for medical therapy","volume":"38","author":"Zheng","year":"2020","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jacbts.2026.101595_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tcm.2012.09.003","article-title":"Visualizing novel concepts of cardiovascular calcification","volume":"23","author":"Hjortnaes","year":"2013","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101595_bib11","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacbts.2026.101595_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejim.2022.03.031","article-title":"Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology","volume":"100","author":"van Ruiten","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jcin.2024.11.036","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on the progression of aortic stenosis","volume":"18","author":"Shah","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacbts.2026.101595_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.3145","article-title":"Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: the BIO-AS study","volume":"26","author":"Scisciola","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2026.101595_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIRCRESAHA.113.301036","article-title":"Macrophage-derived matrix vesicles: an alternative novel mechanism for microcalcification in atherosclerotic plaques","volume":"113","author":"New","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2026.101595_bib16","article-title":"The interplay between TGF-beta signaling and cell metabolism","volume":"10","author":"Liu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jacbts.2026.101595_bib17","first-page":"1230","article-title":"Coronary microvascular reserve and outcome in aortic stenosis: Pathophysiological significance vs. clinical relevance","volume":"38","author":"Lancellotti","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2026.101595_bib18","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jcin.2024.12.025","article-title":"SGLT2 Inhibition in aortic stenosis: a therapy for the ventricle, the valve, or both?","volume":"18","author":"Lindman","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacbts.2026.101595_bib19","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jcmg.2022.04.025","article-title":"Insights into the metabolic aspects of aortic stenosis with the use of magnetic resonance imaging","volume":"15","author":"Monga","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacbts.2026.101595_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12933-024-02329-5","article-title":"Myocardial transcriptomic analysis of diabetic patients with aortic stenosis: key role for mitochondrial calcium signaling","volume":"23","author":"Cherpaz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacbts.2026.101595_bib21","article-title":"Stearic acid alleviates aortic medial degeneration through maintaining mitochondrial dynamics homeostasis via inhibiting JNK\/MAPK signaling","volume":"27","author":"Wang","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.jacbts.2026.101595_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156144","article-title":"Metabolites-mediated posttranslational modifications in cardiac metabolic remodeling: Implications for disease pathology and therapeutic potential","volume":"165","author":"Guo","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.jacbts.2026.101595_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1410832","article-title":"Mitochondrial dysfunction and metabolic reprogramming induce macrophage pro-inflammatory phenotype switch and atherosclerosis progression in aging","volume":"15","author":"Vendrov","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacbts.2026.101595_bib24","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202301710RR","article-title":"Metabolic profiling of aortic stenosis and hypertrophic cardiomyopathy identifies mechanistic contrasts in substrate utilization","volume":"38","author":"Pal","year":"2024","journal-title":"FASEB J"},{"key":"10.1016\/j.jacbts.2026.101595_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pbiomolbio.2023.03.003","article-title":"Glycometabolism reprogramming: Implications for cardiovascular diseases","volume":"179","author":"Peng","year":"2023","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.jacbts.2026.101595_bib26","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/eurheartj\/ehx001","article-title":"Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic importance of microvascular dysfunction in aortic stenosis (PRIMID AS) study","volume":"38","author":"Singh","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2026.101595_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jacbts.2026.101595_bib28","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3390\/healthcare12232464","article-title":"Hemodynamic effects of SGLT2 inhibitors in patients with and without diabetes mellitus-a narrative review","volume":"12","author":"Brata","year":"2024","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.jacbts.2026.101595_bib29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacbts.2026.101595_bib30","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacbts.2026.101595_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacbts.2026.101595_bib32","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2026.101595_bib33","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin Ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2026.101595_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacbts.2026.101595_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.992937","article-title":"Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacbts.2026.101595_bib36","article-title":"Dapagliflozin attenuates myocardial fibrosis by inhibiting the TGF-beta1\/Smad signaling pathway in a normoglycemic rabbit model of chronic heart failure","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacbts.2026.101595_bib37","article-title":"Direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.33594\/000000772","article-title":"Dapagliflozin, An SGLT2 inhibitor, improves endothelial cell energy metabolism through enhanced mitochondrial respiration","volume":"59","author":"Walczak","year":"2025","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jacbts.2026.101595_bib39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacbts.2026.101595_bib40","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacbts.2026.101595_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacbts.2026.101595_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1295463","article-title":"Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacbts.2026.101595_bib43","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","article-title":"Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived beta cells","volume":"23","author":"Alsereidi","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacbts.2026.101595_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106448","article-title":"Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes","volume":"184","author":"Marfella","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jacbts.2026.101595_bib45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.atherosclerosis.2010.07.047","article-title":"Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration","volume":"213","author":"Breyne","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacbts.2026.101595_bib46","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/ATVBAHA.119.313248","article-title":"NFkappaB (Nuclear factor kappa-light-chain enhancer of activated B cells) activity regulates cell-type-specific and context-specific susceptibility to calcification in the aortic valve","volume":"40","author":"Gee","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2026.101595_bib47","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.pharep.2013.12.004","article-title":"Berberine inhibits LPS-induced TF procoagulant activity and expression through NF-kappaB\/p65, Akt and MAPK pathway in THP-1 cells","volume":"66","author":"Gao","year":"2014","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jacbts.2026.101595_bib48","doi-asserted-by":"crossref","first-page":"636","DOI":"10.20452\/pamw.791","article-title":"Evidence for tissue factor expression in aortic valves in patients with aortic stenosis","volume":"119","author":"Natorska","year":"2009","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.jacbts.2026.101595_bib49","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1160\/TH10-09-0612","article-title":"Fibrin presence within aortic valves in patients with aortic stenosis: association with in vivo thrombin generation and fibrin clot properties","volume":"105","author":"Natorska","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacbts.2026.101595_bib50","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ejechocard\/jep048","article-title":"Does diabetes accelerate progression of calcific aortic stenosis?","volume":"10","author":"Kamalesh","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacbts.2026.101595_bib51","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s10753-011-9384-7","article-title":"Does diabetes accelerate the progression of aortic stenosis through enhanced inflammatory response within aortic valves?","volume":"35","author":"Natorska","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.jacbts.2026.101595_bib52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12933-020-01068-7","article-title":"Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes","volume":"19","author":"Kopytek","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacbts.2026.101595_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015261","article-title":"Pathological role of receptor for advanced glycation end products in calcified aortic valve stenosis","volume":"9","author":"Saku","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacbts.2026.101595_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00395-012-0306-0","article-title":"Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products","volume":"107","author":"Li","year":"2012","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jacbts.2026.101595_bib55","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1007\/s00125-021-05545-w","article-title":"Diabetes concomitant to aortic stenosis is associated with increased expression of NF-kappaB and more pronounced valve calcification","volume":"64","author":"Kopytek","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacbts.2026.101595_bib56","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.33963\/KP.a2021.0137","article-title":"Diabetes mellitus as a risk factor for aortic stenosis: from new mechanisms to clinical implications","volume":"79","author":"Natorska","year":"2021","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.jacbts.2026.101595_bib57","article-title":"Empagliflozin rescues pro-arrhythmic and Ca(2+) homeostatic effects of transverse aortic constriction in intact murine hearts","volume":"14","author":"Wen","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacbts.2026.101595_bib58","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00395-024-01067-9","article-title":"Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2","volume":"119","author":"Chen","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jacbts.2026.101595_bib59","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/eurheartj\/ehae829","article-title":"Calcific aortic stenosis: omics-based target discovery and therapy development","volume":"46","author":"Blaser","year":"2025","journal-title":"Eur Heart J"},{"issue":"Supplement 1","key":"10.1016\/j.jacbts.2026.101595_bib60","article-title":"Sirt1 in focus: unveiling molecular insights and therapeutic prospects in calcific aortic stenosis with sglt2i inhibitors","volume":"120","author":"Valerio","year":"2024","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.jacbts.2026.101595_bib61","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacbts.2024.02.012","article-title":"Human aortic stenotic valve-derived extracellular vesicles induce endothelial dysfunction and thrombogenicity through AT1R\/NADPH oxidases\/SGLT2 pro-oxidant pathway","volume":"9","author":"Hmadeh","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacbts.2026.101595_bib62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12933-024-02504-8","article-title":"SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)","volume":"23","author":"Paolisso","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacbts.2026.101595_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.102462","article-title":"Sodium glucose co-transporter 2 inhibitors in patients with heart failure and transcatheter aortic valve replacement","volume":"5","author":"Yasmin","year":"2026","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacbts.2026.101595_bib64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.amjcard.2026.02.043","article-title":"Association of GLP-1 receptor agonist and SGLT2 inhibitor with cardiovascular outcomes after transcatheter aortic valve replacement","volume":"266","author":"Fahoury","year":"2026","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacbts.2026.101595_bib65","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.3390\/jcm14197001","article-title":"Association of SGLT2 inhibitors with mortality and bioprosthesis valve failure after TAVR: a propensity-matched cohort study","volume":"14","author":"Morel","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacbts.2026.101595_bib66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ihj.2024.06.009","article-title":"Role of Empagliflozin in heart failure with severe aortic stenosis before valve replacement: EASTER-HF study","volume":"76","author":"Jariwala","year":"2024","journal-title":"Indian Heart J"},{"key":"10.1016\/j.jacbts.2026.101595_bib67","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in patients undergoing transcatheter aortic-valve implantation","volume":"392","author":"Raposeiras-Roubin","year":"2025","journal-title":"N Engl J Med"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X26001142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X26001142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:31:05Z","timestamp":1789749065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X26001142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2452302X26001142"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2026.101595","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2026.101595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101595"}}